Scientist, Analytical Sciences / QC

Senior Director, Commercial Insights & Analytics

Senior Scientist, Chemical Development

Associate Director, Medical Writing

Associate Director, Formulation Sciences 

Associate Director, Analytical Sciences

Senior Manager, Corporate Communications

Counsel, Legal Affairs

Associate Medical Director, Drug Safety and Pharmacovigilance

Associate Director / Director, Statistical Programming

Senior Manager, Clinical Operations

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Nuvalent is using structure-based drug discovery to create precision medicines for cancer patients. Kinase inhibitors have driven the target therapy revolution in oncology, however, clinical utility is limited by the kinase resistance and selectivity problems. The former is caused by cancer mutations in kinases that become resistant to inhibitors and the latter is due to the similar structural drug binding site of different kinases causing off-target effects. Nuvalent is overcoming the challenges of resistance and selectivity by using structure-based design with clinical insight to find small molecules that inhibit clinically proven kinase targets. Nuvalent’s most advanced drug, NVL-520, targets the kinase ROS1 and is being investigated for patients with non-small cell lung cancer.

<p>Nuvalent is using structure-based drug discovery to create precision medicines for cancer patients. Kinase inhibitors have driven the target therapy revolution in oncology, however, clinical utility is limited by the kinase resistance and selectivity problems. The former is caused by cancer mutations in kinases that become resistant to inhibitors and the latter is due to the similar structural drug binding site of different kinases causing off-target effects. Nuvalent is overcoming the challenges of resistance and selectivity by using structure-based design with clinical insight to find small molecules that inhibit clinically proven kinase targets. Nuvalent’s most advanced drug, NVL-520, targets the kinase ROS1 and is being investigated for patients with non-small cell lung cancer.</p>


Find a biotech startup job.